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Low-dose aspirin use and survival in
colorectal cancer: results from a
population-based cohort study
Ronan T. Gray1*, Helen G. Coleman1, Carmel Hughes2, Liam J. Murray1 and Chris R. Cardwell1
Abstract
Background: Aspirin has been proposed as a novel adjuvant agent in colorectal cancer (CRC). Six observational
studies have reported CRC-specific survival outcomes in patients using aspirin after CRC diagnosis but the results
from these studies have been conflicting. Using a population-based cohort design this study aimed to assess if
low-dose aspirin use after diagnosis reduced CRC-specific mortality.
Methods: A cohort of 8391 patients with Dukes’ A-C CRC (2009–2012) was identified from the Scottish Cancer
Registry and linked to national prescribing and death records. Adjusted hazard ratios (HRs) and 95% confidence
intervals (CIs) for CRC-specific mortality were calculated using time-dependent Cox regression.
Results: There were 1064 CRC-specific deaths after a median follow-up of 3.6 years. Post-diagnostic low-dose
aspirin use was not associated with a reduction in CRC-specific mortality either before or after adjustment for
confounders (adjusted HR = 1.17, 95% CI 1.00–1.36). In sensitivity analysis pre-diagnostic low-dose aspirin was also
not associated with reduced CRC-specific mortality (adjusted HR = 0.96, 95% CI 0.88–1.05).
Conclusion: Low-dose aspirin use, either before or after diagnosis, did not prolong survival in this population-based
CRC cohort.
Keywords: Aspirin, Colorectal cancer, Survival, Pharmaco-epidemiology
Background
Numerous observational studies and long term follow-
up of randomised trials (of aspirin for cardiovascular
indications) suggest that aspirin use is associated with a
reduced risk of colorectal neoplasia [1]. Clinical trails
have also confirmed that aspirin can reduce the risk of
developing recurrent adenomatous polyps [2] in the gen-
eral population and incident colorectal cancer (CRC) in
Lynch syndrome carriers [3]. More recently, further evi-
dence from long-term follow-up of these cardiovascular
trials suggests aspirin could reduce metastases in CRC
patients and therefore could have utility in CRC treat-
ment [4]. To date, six epidemiological studies [5–10]
have investigated the association between aspirin use
after diagnosis and CRC-specific mortality. However,
these studies reached different conclusions (two ob-
served no association [5, 6] whilst four observed marked
reductions [7–10]), and had various limitations including
small sample size, [6] restriction to subgroups, [6] the
potential for biased estimates (described later) [7, 8] and
self-reported exposure ascertainment [9]. Although add-
itional studies have investigated post-diagnostic aspirin
use and all-cause mortality in CRC, [11] results of these
studies could reflect non-cancer related events. Cancer-
specific mortality limits events to those related to the
cancer and represents a more specific endpoint for
evaluating the efficacy of an adjuvant therapy [12].
Additional studies assessing aspirin use after diagnosis
and CRC survival are therefore warranted to investigate
the potential role of adjuvant aspirin treatment in CRC.
We therefore investigated whether post-diagnostic as-
pirin use was associated with improved CRC-specific
mortality in a Scottish population-based CRC cohort.
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The study utilised linkages between national datasets
from Scotland including the Scottish Cancer Registry
(SMR06), the Prescribing Information System (available
from January 2009 to January 2015), the General/Acute
Inpatient and Day Case dataset (SMR01), the Outpatient
Attendance dataset (SMR00) and the National Records
of Scotland Death Records. Linkages between data
sources were conducted using the Community Health
Index number (unique to individuals in Scotland). The
Privacy Advisory Committee of the National Health
Service (NHS) National Services Scotland (NSS) approved
the study.
Study population
A cohort of newly diagnosed Dukes’ A-C CRC patients
was identified within the Scottish Cancer Registry (ICD
codes of the colon C18 or rectum C20 including the
recto-sigmoid junction C19) between January 2009 and
December 2012. Cohort members with previous cancer
diagnoses (after January 1999), apart from in situ neo-
plasms and non-melanoma skin cancers, were excluded
(Fig. 1). Deaths were identified from National Records of
Scotland with coverage up to 1st January 2015 (or from
Scottish Cancer Registry death records) with CRC-
specific deaths defined as those with underlying cause of
death ICD code C18, C19, C20, C21 (anus) or C26
(other and ill-defined digestive organs). Deaths in the
first year after CRC diagnosis were removed, this restric-
tion reduces the likelihood of including patients who
were not recurrence-free at exposure [13]. Patients were
therefore followed up from 1 year after CRC diagnosis
to death, the date they left Scotland or 1st January 2015.
Exposure data
The Prescribing Information System (available from
January 2009 to January 2015) holds all medicines dis-
pensed in the community in Scotland [14]. Low-dose
(75 mg) aspirin exposure was identified from dispensing
records within this database. A quantity of 28 tablets
was assumed for the less than 0.1% of prescriptions
where quantity was assumed incorrect. Daily defined
doses (DDD) were calculated based on the quantity of
tablets as defined by the World Health Organisation
[15]. Aspirin use was investigated as a time-varying co-
variate (patients were initially considered non-users and
then users after a lag of 6 months after their first aspirin
prescription) [13, 16]. This lag ensured new prescrip-
tions in the six-month period prior to death were not
considered as they may reflect end of life treatment.
Dose (exposure)-response analyses were conducted with
individuals considered non-users prior to 6 months after
first use (i.e. aspirin users were considered non-users
until the lag period passed), a short term user between 6
months after first use and 6 months after the 12th pre-
scription (i.e. up to 1 year of exposure after the lag
period) and a longer term user after this time (users for
more than 1 year after the lag period).
Covariates
Data available from the Scottish Cancer Registry in-
cluded Dukes’ stage, histological grade and surgery,
chemotherapy and radiotherapy in the 6 months after
diagnosis. Comorbidities that contribute to the Charlson
index were determined prior to diagnosis based upon
ICD10 diagnosis codes, as described previously, [17] in
Scottish hospital inpatient (SMR01) and outpatient data
(SMR00). The SMR01 dataset contains information on
hospital diagnoses and operations and the SMR00 data-
set (both available from January 1999 to January 2015)
contains diagnosis and procedures from new and follow
up appointments at outpatient clinics. A deprivation
measure was determined using the 2009 Scottish Index
of Multiple Deprivation based upon postcode of resi-
dence [18].
Statistical analysis
Time-dependent Cox regression models were used to
calculate hazard ratios (HRs) for CRC-specific death and
95% confidence intervals (CIs) for aspirin users com-
pared with non-users as described previously [19]. Mul-
tivariable analyses adjusted for the potential confounders
Fig. 1 Patient selection for analysis in cohort study
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age, sex, year of diagnosis, deprivation, site (colon or
rectum), stage, grade, cancer treatment within 6 months
(radiotherapy, chemotherapy, surgery), comorbidities
(prior to diagnosis, including acute myocardial infarc-
tion, congestive heart failure, peripheral vascular disease,
cerebral vascular accident, pulmonary disease, peptic
ulcer, liver disease, diabetes, renal disease) and statin use
(as a time-varying covariate). Analyses were conducted
by number of tablets and repeated for all-cause mortality.
Subgroup analyses were conducted by site (colon or
rectal) and pre-diagnostic aspirin use (de novo versus
pre- and post-diagnostic aspirin use).
Sensitivity analysis was conducted by increasing the
lag period (the time from first dispensed aspirin pre-
scription to when the patient started to accrue aspirin
exposure follow-up time) to 1 year. A simplified analysis
was also performed using Cox regression to assess sur-
vival in aspirin users compared to non-users in the first
year after colorectal cancer diagnosis in individuals living
more than 1 year after diagnosis (follow-up commenced
1 year from the date of diagnosis until the date of last
data collection); this controls for immortal time bias
without requiring time-varying covariates [20]. Finally,
an analysis was conducted based upon aspirin prescrip-
tions in the year prior to diagnosis (excluding patients
diagnosed in 2009 for whom a full year of prescription
records prior to diagnosis may not be available), not
excluding deaths in the first year after diagnosis and
including all colorectal cancer patients regardless of
Dukes’ stage. The adjusted model for pre-diagnostic as-
pirin use did not include stage, grade or cancer treat-
ment to avoid over adjustment [21, 22] as they could be
on the causal pathway for the association between pre-
diagnostic aspirin use and CRC-specific mortality.
An adjusted post-hoc analysis was undertaken compar-
ing cardiovascular deaths between post-diagnostic aspirin
users and non-users. Cardiovascular deaths were those in
which the underlying death was ICD 10 codes I0–99, G45,
Q20–26, F01 or equivalent ICD-9 codes. The adjusted
model for this analysis was similar to the primary multi-
variable analysis except only non-cardiovascular comor-
bidities (pulmonary disease, peptic ulcer, liver disease,
diabetes, renal disease) were included. All statistical ana-
lyses were conducted in STATA 13 software (StataCorp,
College Station, TX).
Results
A total of 8391 incident Dukes’A to C CRC cases met the
inclusion criteria (Fig. 1), in which there was on average
3.6 years of follow-up after diagnosis (median = 3.6,
range1–6 years). Patient characteristics by aspirin use are
shown in Table 1. Aspirin users in the year after diagnosis
were more likely to be older, male and reside in more de-
prived areas. Stage and grade were generally similar by
aspirin use, but a smaller proportion of aspirin users com-
pared to non-users had Dukes’ C disease (post-diagnostic
use, 32.7% versus 35.5% respectively). Aspirin users were
also more likely to have comorbidities (particularly cardio-
vascular disease and diabetes) and use statins but a smaller
proportion received adjuvant chemotherapy.
Post-diagnostic aspirin use was not associated with re-
duced CRC-specific mortality after adjustment for poten-
tial confounders (HR = 1.17, 95% CI 1.00–1.36) (Table 2).
Results for overall survival were similar, except that the
observed increases in mortality were detected as statisti-
cally significant after adjustment (adjusted HR = 1.21
95%CI 1.07–1.37). Post-hoc analysis confirmed there was a
marked increase in cardiovascular deaths in post-
diagnostic aspirin users compared to non-users (adjusted
HR = 1.63, 95% CI 1.15–2.29).
There was no evidence of an exposure response when
users consuming more (long term users) or less (short
term users) than a 365-day supply were compared with
non-users (Table 2). Stratifying by tumour location did
not greatly alter the size or direction of the association
for CRC-specific mortality (adjusted HR = 1.13, 95% CI
0.94–1.36 versus adjusted HR = 1.26, 95% CI 0.94–1.69
in colon and rectal cancer patients respectively).
The results of the planned sensitivity analyses are doc-
umented in Tables 3 and 4. Repeating the analysis using
a simplified one-year analysis did not demonstrate a sur-
vival benefit for post-diagnostic aspirin use. Interestingly
cancer-specific and overall survival were markedly worse
in de novo post-diagnostic aspirin users (adjusted CRC-
specific survival HR = 1.51, 95% CI 1.12–2.05; adjusted
overall survival HR = 1.53, 95% CI 1.19–1.95) when
post-diagnostic aspirin use versus non-use was stratified
by pre-diagnostic aspirin use. However, when aspirin use
was compared to non-use in the year prior to diagnosis,
there was no association with CRC-specific (adjusted
HR = 0.96, 95% CI 0.88–1.05) or overall survival
(adjusted HR = 0.99, 95% CI 0.92–1.06). Finally, the re-
sults of the main time-varying analysis of post-diagnostic
aspirin use were not greatly altered when the lag period
was increased from 6 to 12 months (adjusted cancer-
specific survival HR = 1.08, 95%CI 0.94–1.26; adjusted
overall survival HR = 1.15, 95% CI 1.03 to 1.29).
Discussion
Low-dose aspirin use after colorectal cancer diagnosis
was not associated with improved CRC-specific sur-
vival in this large Scottish population-based cohort
study. Specifically, low-dose aspirin use was associated
with a 17% increase in CRC-specific mortality, but
this was not statistically significant and did not follow
an exposure response. Overall, in subgroup and sensi-
tivity analyses the findings of the main analyses were
relatively consistent.
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Six observational studies have reported the association
between CRC-specific outcomes and post-diagnostic as-
pirin use in CRC [5–10]. The findings from the present
study add further inconsistency to the evidence base
therefore the differences between the studies should be
discussed. These findings are within the confidence
intervals for the null association our research group pre-
viously reported using linked data from the Clinical
Practice Research Datalink and the English National
Cancer Data Repository (n = 4794, adjusted CRC-
specific survival HR = 0.99, 95% CI 0.86–1.15) [5].
Kothari et al. also reported a null association between
CRC-specific mortality and low-dose aspirin use at CRC
diagnosis, but the study was small and limited to
tumours that were PIK3CA mutant (n = 185) [6].
Notably, our current results do contrast with the in-
verse association reported by McCowan et al. (2013) in a
separate regional Scottish population-based study [8].
Important differences in the statistical analysis could ex-
plain these findings. In particular, their analysis used an
unlagged start/stop time-varying covariate. This poten-
tially introduces bias through reverse causation as deaths
were allocated to the exposed/unexposed group on the
basis of whether the aspirin prescription covered the
death date [5, 23]. In particular, prescription medications
may be stopped as patients enter the terminal phase of
their disease [24]. Failure to include a lag period can
therefore over estimate any association or inadvertently
make it appear that aspirin use is associated with a re-
duced risk of disease progression due to misclassification.
Similarly, Goh et al. (2014) reported a 62% reduction
(HR = 0.38, 95% CI 0.17–0.84) in CRC-specific mortality
among n = 726 post-diagnostic aspirin users utilising a
national prescription database [7]. However the authors
do not describe any method to eliminate immortal time
bias (such as use of a time-varying covariate) which
could artificially create a protective effect [16]. It is also
worth noting that our study only assessed low-dose as-
pirin use, therefore we could not investigate the im-
proved outcomes for predominantly high-dose aspirin
users observed in previous studies [9]. Finally, despite
Table 1 Characteristics of colorectal cancer patients by
post-diagnostic aspirin use
Aspirin use in first year after cancer
diagnosisa
Yes (n = 2150) No (n = 6241)
Number % Number %
Age
< 50 13 0.6 432 6.9
50–59 131 6.1 1113 17.8
60–69 586 27.3 1973 31.6
70–79 934 43.4 1876 30.1
≥ 80 486 22.6 847 13.6
Gender
Men 1387 64.5 3287 52.7
Deprivation (fifth)
1 (most deprived) 447 20.8 1039 16.6
2 497 23.1 1272 20.4
3 429 20.0 1263 20.2
4 412 19.2 1361 21.8
5 (least deprived) 365 17.0 1305 20.9
Tumour location
Colon 1493 69.4 4227 67.7
Rectum/rectosigmoid junction 657 30.6 2014 32.3
Dukes’ stage
A 597 27.8 1683 27.0
B 851 39.6 2340 37.5
C 702 32.7 2218 35.5
Grade
Well differentiated 82 3.8 203 3.3
Moderately differentiated 1646 76.6 4796 76.8
Poorly differentiated 315 14.7 968 15.5
Missing 107 5.0 274 4.4
Treatment (within six months)
Surgery 2020 94.0 5908 94.7
Radiotherapy 192 8.9 679 10.9
Chemotherapy 472 22.0 2167 34.7
Comorbidity before cancer diagnosis
Acute myocardial infarction 300 14.0 103 1.7
Congestive heart failure 135 6.3 94 1.5
Peripheral vascular disease 145 6.7 80 1.3
Cerebral vascular accident 162 7.5 141 2.3
Pulmonary disease 207 9.6 383 6.1
Peptic ulcer 59 2.7 151 2.4
Table 1 Characteristics of colorectal cancer patients by
post-diagnostic aspirin use (Continued)
Aspirin use in first year after cancer
diagnosisa
Yes (n = 2150) No (n = 6241)
Number % Number %
Liver disease 6 0.3 25 0.4
Diabetes 290 13.5 285 4.6
Renal disease 87 4.0 102 1.6
Statin use after diagnosis 1647 76.6 1490 23.9
aRestricted to patients who survived at least 1 year after diagnosis
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using broadly similar methodology in large population-
based CRC cohorts, the results of the current study con-
flict with the modest protective association (adjusted
HR = 0.85 95% CI 0.79, 0.92) observed with three or
more aspirin prescriptions reported by Bains et al. [10].
It is unclear why the results of these studies differ but some
of this could reflect differences in the confounding vari-
ables that were included in multivariable analyses; in par-
ticular, only the current study adjusted for chemotherapy
or radiotherapy use, the presence of comorbid ill-
nesses and deprivation.
The 20% increase in all-cause mortality in aspirin users
compared to non-users in this colorectal cancer cohort
warrants further discussion but as post hoc analysis dem-
onstrated that this increase was driven by cardiovascular
mortality, it seems likely that confounding by indication is
responsible. Residual confounding may also bias the CRC-
specific analyses reported in this study. In particular, the
Table 2 Association between aspirin use after diagnosis and CRC-specific and overall survival in patients with colorectal cancer
Mortality Patients Person years Unadjusted HR
(95% CI)




Aspirin non-user 729 5881 15,957 1.00 (ref. cat.) 1.00 (ref. cat.)
Aspirin user 335 2510 6178 1.22 (1.07, 1.39) 0.003 1.17 (1.00, 1.36) 0.06
1 to 365 DDDs vs. non-user 160 725 2549 1.34 (1.12, 1.59) 0.001 1.23 (1.02, 1.50) 0.03
≥ 365 DDDs vs. non-user 175 1785 3629 1.12 (0.95, 1.33) 0.18 1.10 (0.90, 1.33) 0.36
Overall survival
Aspirin non-user 1035 5881 15,957 1.00 (ref. cat.) 1.00 (ref. cat.)
Aspirin user 600 2510 6178 1.51 (1.37, 1.67) < 0.001 1.21 (1.07, 1.37) 0.002
1 to 365 DDDs vs. non-user 263 725 2549 1.59 (1.39, 1.83) < 0.001 1.26 (1.08, 1.46) 0.004
≥ 365 DDDs vs. non-user 337 1785 3629 1.45 (1.28, 1.65) < 0.001 1.18 (1.02, 1.37) 0.03
Abbreviations: CI confidence interval, CRC colorectal cancer, DDD daily defined dose, HR hazard ratio
aMultivariable model contains age, sex, year of diagnosis, deprivation, site (colon or rectum), stage, grade, cancer treatment within 6 months (radiotherapy,
chemotherapy, surgery), comorbidities (prior to diagnosis, including acute myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral
vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease) and statin use (as a time-varying covariate)
Table 3 Sensitivity analyses for the association between aspirin use and CRC-specific survival in patients with colorectal cancer
Aspirin user Aspirin non-user
Mortality Patients Person years Mortality Patients Person years Unadjusted HR
(95% CI)




Post-diagnostic aspirin use (fixed time exposure in first year)a
Aspirin user vs.
non-user
310 2150 5692 754 6241 16,442 1.19 (1.05, 1.36) 0.01 1.10 (0.94, 1.29) 0.22
Post-diagnostic aspirin use versus non-use stratified by pre-diagnostic use (excludes 2009 cases)b
Pre-diagnostic users 168 1333 2983 46 257 614 0.75 (0.54,1.04) 0.08 0.80 (0.56,1.13) 0.20
Pre-diagnostic
non-users
51 435 744 467 4301 9930 1.52 (1.13,2.03) 0.01 1.51 (1.12,2.05) 0.01
Aspirin use vs. non-use in year before colorectal cancer diagnosis (excludes 2009 cases)c
Aspirin user vs.
non-user
1104 2853 6460 2551 7555 18,652 1.23 (1.14, 1.32) < 0.001 0.96 (0.88, 1.05) 0.37
Abbreviations: CI confidence interval, CRC colorectal cancer, HR hazard ratio
aModel contains age, sex, year of diagnosis, deprivation, site (colon or rectum), stage, grade, cancer treatment within six months (radiotherapy, chemotherapy,
surgery), comorbidities (prior to diagnosis, including acute myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral vascular accident,
pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease) and statin use (in first year after diagnosis)
bExcluding patients diagnosed in 2009 (who do not have complete prescription records for year before diagnosis). Based upon main time-varying covariate
multivariable model containing age, sex, year of diagnosis, deprivation, site (colon or rectum), stage, grade, cancer treatment within 6 months (radiotherapy,
chemotherapy, surgery), comorbidities (prior to diagnosis, including acute myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral
vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease) and statin use (as time-varying covariate)
cExcluding patients diagnosed in 2009 (who do not have complete prescription records for year before diagnosis) but not excluding patients who die within
1 year of diagnosis; adjusted model contains age, sex, year of diagnosis, deprivation, site (colon or rectum), comorbidities (prior to diagnosis, including acute
myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal
disease) and statin use (in year prior to diagnosis)
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prevalence of cardiovascular disease in Scotland is
amongst the highest in Europe and is the highest of all the
regions in the UK [25]. Cardiovascular disease is known to
be associated with reduced physical activity and obesity,
two factors that are independently associated with worse
survival outcomes in colorectal cancer [26–28]. Unfortu-
nately it was not possible to adjust for these lifestyle vari-
ables in the current cohort. Therefore, as low-dose aspirin
is prescribed for the secondary prevention of cardiovascu-
lar disease, obesity and physical inactivity may be associ-
ated with both the exposure and the outcome of interest.
The strengths of the current study include its size,
population-based design and use of dispensing informa-
tion with detailed information. The contemporary nature
of the cohort and its population-based approach also en-
hance the external validity of the results. One of the
main limitations is that as this is an observational study
there is the potential for residual confounding. In
addition to the absence of information on lifestyle vari-
ables, the comorbidity data may not be complete as it
relied on hospital records rather than GP recorded diag-
noses or patient interviews. Also, while dispensing infor-
mation is more robust than prescribing information,
compliance cannot be confirmed. Over-the-counter
usage could also result in some users being misclassified
but a previous UK study using GP prescribing data esti-
mated that 70–80% [29] of aspirin use in the age-group
we investigated was prescription-based, while another
showed little evidence of misclassification by aspirin
usage when compared with patient recall [30]. Cause of
death can also be misclassified when relying on data
from national statistics records. We were also unable to
assess cyclooxygenase 2 (COX-2) expression or PIK3CA
mutation status, two potential molecular biomarkers
that may predict response to aspirin therapy [9, 31, 32].
Importantly though, while these markers did differenti-
ate tumours more likely to benefit from aspirin use in
the these studies, the survival benefit associated with as-
pirin use also existed before stratification of the cohorts
by molecular profile [9, 32]. Finally, follow-up in the
current cohort is relatively short (median = 3.6 years).
However, in a separate Scottish cohort study, McCowan
et al. demonstrated a survival benefit associated with as-
pirin use after a shorter median follow-up of 2.8 years [8].
Conclusion
In summary, there is inconsistent evidence from previ-
ous observational studies on the association between
post-diagnostic low-dose aspirin use and improved
CRC-specific survival. In the present study we did not
find any evidence of a reduction in cancer-specific mor-
tality in aspirin users. Although we observed a small in-
crease in all-cause mortality this seems likely to reflect
confounding by indication. For these reasons clinical
trials assessing adjuvant aspirin therapy in colorectal
cancer (NCT02467582; NCT02301286; NCT00565708;
ISRCTN74358648) are keenly anticipated but are not
due to report until at least 2022.
Table 4 Sensitivity analyses for the association between aspirin use and overall survival in patients with colorectal cancer











Post-diagnostic aspirin use (fixed time exposure in first year)a
Aspirin user vs. non-user 554 2150 5692 1081 6241 16,442 1.48 (1.33, 1.64) < 0.001 1.17 (1.03, 1.32) 0.01
Post-diagnostic aspirin use versus non-use stratified by pre-diagnostic use (excludes 2009 cases)b
Pre-diagnostic users 290 1333 2983 70 257 614 0.84 (0.65,1.10) 0.21 0.88 (0.67,1.17) 0.39
Pre-diagnostic
non-users
84 435 744 638 4301 9930 1.79 (1.42,2.25) < 0.001 1.53 (1.19,1.95) 0.001
Aspirin use vs. non-use in year before colorectal cancer diagnosis (excludes 2009 cases)c
Aspirin user vs.
non-user
1506 2853 6460 3117 7555 18,652 1.37 (1.29, 1.46) < 0.001 0.99 (0.92, 1.06) 0.77
Abbreviations: CI confidence interval, HR hazard ratio
aModel contains age, sex, year of diagnosis, deprivation, site (colon or rectum), stage, grade, cancer treatment within six months (radiotherapy, chemotherapy,
surgery), comorbidities (prior to diagnosis, including acute myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral vascular accident,
pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease) and statin use (in first year after diagnosis)
bExcluding patients diagnosed in 2009 (who do not have complete prescription records for year before diagnosis). Based upon main time-varying covariate
multivariable model containing age, sex, year of diagnosis, deprivation, site (colon or rectum), stage, grade, cancer treatment within 6 months (radiotherapy,
chemotherapy, surgery), comorbidities (prior to diagnosis, including acute myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral
vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease) and statin use (as time-varying covariate)
cExcluding patients diagnosed in 2009 (who do not have complete prescription records for year before diagnosis) but not excluding patients who die within
1 year of diagnosis; adjusted model contains age, sex, year of diagnosis, deprivation, site (colon or rectum), comorbidities (prior to diagnosis, including acute
myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal
disease) and statin use (in year prior to diagnosis)
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CI: Confidence interval; CRC: Colorectal cancer; DDD: Daily defined dose;
HR: Hazard ratio
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